Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

NCT01484080 is registered in ClinicalTrials.gov with Centro Nacional de Investigaciones Oncologicas CARLOS III as lead sponsor.

NCT NCT01484080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01484080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
Lead sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2011
Completion date
April 30, 2014
Enrollment
140 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer